This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

This study has been completed.
Dr. Falk Pharma GmbH
Information provided by:
Rafa Laboratories Identifier:
First received: August 9, 2005
Last updated: August 26, 2005
Last verified: August 2005
Twenty-four (2 x 12) patients with intestinal graft versus host disease (GVHD) Grades 2, 3 or 4 will be treated with budesonide 3mg three times daily or placebo for 12 weeks. All of the patients will receive cyclosporine and by mouth (po) prednisone or intravenous (IV) methylprednisone with a starting dose of 2mg/kg/day (standard anti-GVHD treatment). Doses of steroids will be decreased by approximately 10% or 10mg per week (depending upon patient’s weight) upon response to therapy, defined as a decrease of volume of diarrhea by 50% per day, decrease in abdominal pain and no presence of bloody stool. Patients with Grades 3 or 4 will be withdrawn from the study if there is no response after one week of therapy. Patients with Grade 2 may continue with no decrease in prednisone dose until response is achieved.

Condition Intervention Phase
Graft Vs Host Disease Drug: Budesonide Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD

Resource links provided by NLM:

Further study details as provided by Rafa Laboratories:

Estimated Enrollment: 24
Study Start Date: January 2001
Estimated Study Completion Date: August 2005
  Show Detailed Description


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with clinical and biopsy proven Grades 2, 3 or 4 intestinal GVHD
  • Patients with a negative stool culture
  • Male or female patients aged between 18 – 70 years
  • Signed written informed consent of the patient

Exclusion Criteria:

  • Uncertain GVHD diagnosis (other causes of intestinal disease are possible)
  • Severe other disease which may influence the patient prognosis
  • Contraindication to the use of steroids
  • Patient’s inability to swallow the study medications
  • Concurrent use of non-steroidal anti-inflammatory drug (NSAID)
  • Known spontaneous or iatrogenic disturbances of thrombocyte aggregation or blood clotting.
  • Kidney dysfunction with creatinine level higher than 2mg/dl
  • Patients on preventative antimicrobial therapy with the exception of Resprim® (sulfamethoxazole and trimethoprim)
  • Patients taking somatostatin
  • Patients taking anti-GVHD medication with the exception of steroids (maximum dose of prednisone or methylprednisolone 2mg/kg/day) and cyclosporine A or tacrolimus
  • Pregnancy or lactation
  • Insufficient contraception protection
  • Participation in another clinical study within the last 30 days.
  • Mental condition rendering the patient unable to understand the nature or scope and possible consequences of the study and/or evidence of an uncooperative attitude.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00128739

Hadassah Medical Organization,
Jerusalem, Israel, 91120
Sponsors and Collaborators
Rafa Laboratories
Dr. Falk Pharma GmbH
Principal Investigator: Michael Y Shapira, MD Hadassah Medical Organization
  More Information Identifier: NCT00128739     History of Changes
Other Study ID Numbers: 25-23/02/01
Study First Received: August 9, 2005
Last Updated: August 26, 2005

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 18, 2017